In this study, the biological studies revealed that compound 2 can strongly and dose-dependently inhibited the peak currents of Cav3.1 low voltage-gated Ca2+ channel (LVGCC), an important therapeutic target for absence epilepsy, neuropathic pain, Parkinson’s disease, and insomnia [20–22], with an IC50 value of 3.5 μM. Meanwhile, 1, 3, and 4 were inactive at the concentration of 30 μM. In this note, the isolation and structural elucidation of these compounds were described, as well as their inhibitions on Cav3.1 LVGCC. This evidence concerns the gene CACNA1G and Parkinson disease.